References
- Flear CT, Gill GV, Burn J. Hyponatraemia: mechanisms and management. Lancet 1981;2:26-31
- Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169-72
- Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol 2010;162(Suppl 1):S5-12
- Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin 2008;24:1601-8
- Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol 2009;29:227-38
- Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS ONE 2013;8:e80451
- Gill G, Huda B, Boyd A, et al. Characteristics and mortality of severe hyponatraemia—a hospital-based study. Clin Endocrinol (Oxf) 2006;65:246-9
- Wald R, Jaber BL, Price LL, et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170:294-302
- Hoorn EJ, Rivadeneira F, van Meurs JB, et al. Mild hyponatremia as a risk factor for fractures: The Rotterdam Study. J Bone Miner Res 2011;26:1822-8
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126(10 Suppl 1):S1-42
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014;29(Suppl 2):i1-i39
- Chantzichristos D, Drougge H, Dahm P, et al. Svenska Endokrinologföreningen. Available at: http://endokrinologforeningen.se/index.php/nyheter/52-2012-02-09-svenskt-vardprogram-for-hyponatremi. Accessed April 2, 2014
- Runkle I, Navarro A, Pose A, et al. El tratamiento de la hiponatremia secundaria al síndrome de secreción inadecuada de la hormona antidiurética. Med Clin (Barc) 2013;141:507.e1-507.e10
- Grossman A, Bouloux PM, Thatcher N, et al. Expert panel guidelines for the treatment of hyponatraemia. Draft version, presented at Stratford, UK, February 7–8, 2013
- Samsca (Tolvaptan): Drug Safety Communication - FDA limits duration and usage due to possible liver injury leading to organ transplant or death. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm. Accessed April 30, 2013
- Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957;23:529-42
- Soupart A, Coffernils M, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7:742-7
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112
- Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-32
- Bichet DG. What is the role of vaptans in routine clinical nephrology? Clin J Am Soc Nephrol 2012;7:700-3